Table 1 Clinical characteristics of study subjects.
Groups (WHO grade) | Number of subjects | Age (Mean + SD) | Male (%) | Molecular alteration (n) | |
|---|---|---|---|---|---|
IDH1 or IDH2 status (mutant/wildtype/NOS) | 1p/19q codeletion (yes/no/NOS) | ||||
Gliomas (2–4) | 317 | 53.4 ± 12.0 | 50.7% | 84/230/3 | 67/239/11 |
Astrocytoma | 49 | 42.3 ± 10.7 | 57.1% | 49/0/0 | 0/48/1 |
Astrocytoma (2) | 21 | 45.2 ± 10.8 | 61.9% | 21/0/0 | 0/21/0 |
Astrocytoma (3) | 12 | 38.5 ± 9.1 | 75.0% | 12/0/0 | 0/11/1 |
Astrocytoma (4) | 16 | 41.3 ± 11.2 | 37.5% | 16/0/0 | 0/16/0 |
Oligodendroglioma | 38 | 44.9 ± 9.6 | 57.9% | 35/0/3 | 38/0/0 |
Oligodendroglioma (2) | 16 | 46.1 ± 7.5 | 50.0% | 14/0/2 | 16/0/0 |
Oligodendroglioma (3) | 22 | 44.0 ± 11.0 | 63.6% | 21/0/1 | 22/0/0 |
Glioblastoma (4) | 230 | 54.2 ± 15.2 | 50.9% | 0/230/0 | 29/191/10 |
Population controls | 480 | 54.8 ± 9.5 | 49.4% | – | – |
